Jingyun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jingyun Wang has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Qixian Chen
Innovation Center of Yangtze River Delta Zhejiang University Jiaxing Zhejiang China
25 shared publications - Xiaojun Peng
Dalian University of Technology
21 shared publications - Haidong Li
Dalian University of Technology
17 shared publications Hongyan Cui
Innovation Center of Yangtze River Delta
17 shared publicationsLiuwei Zhang
Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, Zhejiang 314100, China
16 shared publicationsMing Qian
School of Bioengineering, Dalian University of Technology, 2 Linggong Road, Hi-tech Zone, Dalian, 116024, China
16 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (36) , 17319-17331
A dual-lock strategy for tumor-specific pyroptosis activation plus gas synergism
This work presents a gas‑synergistic dual‑lock pyroptosis inducer that enables tumor‑specific recognition and efficient ICD induction via GSH/NIR‑triggered photodynamic amplification, offering a new approach for multifunctional tumor immunotherapy.
- 23 September 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 17 (36) , 17319-17331
Open AccessA dual-lock strategy for tumor-specific pyroptosis activation plus gas synergism
This work presents a gas‑synergistic dual‑lock pyroptosis inducer that enables tumor‑specific recognition and efficient ICD induction via GSH/NIR‑triggered photodynamic amplification, offering a new approach for multifunctional tumor immunotherapy.
- 10 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Glutathione-Triggered Unleashing of Protease K Prodrug Suppressed Primary Tumors and Its Metastasis with Stimulated Anti-tumor Immunity
Protein therapeutics have garnered significant enthusiasm for oncological applications, owing to their exquisite specificity and intrinsic bioactivity. Yet, proteins remain constrained by limited transcellular permeability and proteolytic susceptibility during delivery. To circumvent these impediments, we engineered a redox-responsive protein prodrug, RP-ss-PK, via covalent conjugation of cytotoxic proteinase K (PK) to a multifunctional polymer, RGD-PEG-ss-NPC. This linear hetero-difunctional PEG scaffold contains a cyclic RGD peptide at the α-terminus for integrin-mediated tumor targeting and a 4-nitrophenyl ethyl carbonate (NPC) group at the ω-terminus for site-specific conjugation to amine-rich lysine residues on PK. An internal disulfide linker (-ss-) renders the prodrug cleavable in the presence of intracellular glutathione (GSH). Upon systemic administration, RP-ss-PK selectively accumulates within neoplastic lesions via RGD-integrin (αvβ3/αvβ5) recognition. Endocytosis exposes the disulfide tether to the cytosolic glutathione milieu, triggering reductive cleavage and subsequent liberation of native, fully active PK. The unleashed protease initiates indiscriminate proteolysis that precipitates rapid tumor cell death, accompanied by plasma-membrane permeabilization. This membrane disruption facilitates the extracellular release of damage-associated molecular patterns (DAMPs), thereby igniting anti-tumor immunity and remodeling the tumor microenvironment. Collectively, this prodrug paradigm not only amplifies the tumor-selective delivery of protein therapeutics but also exemplifies a facile, broadly applicable strategy for intracellular activation and functional restoration of protein cargos. Our findings establish RP-ss-PK as a versatile platform poised for the targeted protein treatment of diverse pathologies.
- 10 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Glutathione-Triggered Unleashing of Protease K Prodrug Suppressed Primary Tumors and Its Metastasis with Stimulated Anti-tumor Immunity
Protein therapeutics have garnered significant enthusiasm for oncological applications, owing to their exquisite specificity and intrinsic bioactivity. Yet, proteins remain constrained by limited transcellular permeability and proteolytic susceptibility during delivery. To circumvent these impediments, we engineered a redox-responsive protein prodrug, RP-ss-PK, via covalent conjugation of cytotoxic proteinase K (PK) to a multifunctional polymer, RGD-PEG-ss-NPC. This linear hetero-difunctional PEG scaffold contains a cyclic RGD peptide at the α-terminus for integrin-mediated tumor targeting and a 4-nitrophenyl ethyl carbonate (NPC) group at the ω-terminus for site-specific conjugation to amine-rich lysine residues on PK. An internal disulfide linker (-ss-) renders the prodrug cleavable in the presence of intracellular glutathione (GSH). Upon systemic administration, RP-ss-PK selectively accumulates within neoplastic lesions via RGD-integrin (αvβ3/αvβ5) recognition. Endocytosis exposes the disulfide tether to the cytosolic glutathione milieu, triggering reductive cleavage and subsequent liberation of native, fully active PK. The unleashed protease initiates indiscriminate proteolysis that precipitates rapid tumor cell death, accompanied by plasma-membrane permeabilization. This membrane disruption facilitates the extracellular release of damage-associated molecular patterns (DAMPs), thereby igniting anti-tumor immunity and remodeling the tumor microenvironment. Collectively, this prodrug paradigm not only amplifies the tumor-selective delivery of protein therapeutics but also exemplifies a facile, broadly applicable strategy for intracellular activation and functional restoration of protein cargos. Our findings establish RP-ss-PK as a versatile platform poised for the targeted protein treatment of diverse pathologies.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (60) , 15015-15018
A Multimodal Theranostic Agent for Specific Imaging and Inducing Immunogenic Cell Death of β-galactosidase-Overexpressing Ovarian Cancer Cells
A β-galactosidase-activatable photosensitizer, Scy-β, was rationally designed and synthesized, enabling near-infrared fluorescence/photoacoustic (NIFL/PA) dual-modal imaging of ovarian cancer, selective ovarian cancer cells killing, and efficient induction of immunogenic cell death...
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (60) , 15015-15018
A Multimodal Theranostic Agent for Specific Imaging and Inducing Immunogenic Cell Death of β-galactosidase-Overexpressing Ovarian Cancer Cells
A β-galactosidase-activatable photosensitizer, Scy-β, was rationally designed and synthesized, enabling near-infrared fluorescence/photoacoustic (NIFL/PA) dual-modal imaging of ovarian cancer, selective ovarian cancer cells killing, and efficient induction of immunogenic cell death...
- 12 October 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 388 (Pt 1) , 114318
Unlocking intracellular targets: Smart multistage-responsive polyionic vesicular platforms for advancing protein-based therapy
- 12 October 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 388 (Pt 1) , 114318
Unlocking intracellular targets: Smart multistage-responsive polyionic vesicular platforms for advancing protein-based therapy
- Open Access
- 22 August 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (41) , e202513815
A Photon‐Driven Unimolecular Immunostimulant for Self‐Amplified Pyroptosis and cGAS‐STING Pathway by Destroying the Pyroptosis Checkpoint
Immunotherapy is a groundbreaking approach for clinically treating tumors, but its effectiveness is hindered by the tumor's immunosuppressive environment and lack of immune cell infiltration, enabling tumors to evade the immune system. Although the activation of both innate and adaptive immunities is a promising strategy to counteract this bottleneck, their synergy remains challenging. Therefore, we developed Bio‐Cy, an unprecedented organic unimolecular photosensitive immunostimulant, which stimulates self‐amplifying pyroptosis and cGAS‐STING pathways by disrupting pyroptosis checkpoints to enhance adaptive and innate immunity activation. Mechanistic studies have shown that Bio‐Cy can target cancer cells and be transported to lysosomes via endocytosis, generating reactive oxygen species through a Type I photodynamic mechanism to destroy cancer cells, even under hypoxic conditions. Interestingly, this lysosomal disruption not only activates the caspase‐3/GSDME‐dependent pyroptosis of adaptive immunity through mitochondrial damage by releasing Ca2+, but also enhances the cGAS‐STING innate immune pathway by releasing mitochondrial DNA. More importantly, the initial lysosomal damage impairs protective cellular autophagy, destroying the pyroptosis checkpoint and thus preventing the clearance of damaged mitochondria and amplifying immune responses, ultimately boosting immunotherapy. This strategy effectively treats primary tumors and inhibits metastatic growth, offering a new paradigm for photoimmunotherapy.
- 22 August 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (41) , e202513815
Open AccessA Photon‐Driven Unimolecular Immunostimulant for Self‐Amplified Pyroptosis and cGAS‐STING Pathway by Destroying the Pyroptosis Checkpoint
Immunotherapy is a groundbreaking approach for clinically treating tumors, but its effectiveness is hindered by the tumor's immunosuppressive environment and lack of immune cell infiltration, enabling tumors to evade the immune system. Although the activation of both innate and adaptive immunities is a promising strategy to counteract this bottleneck, their synergy remains challenging. Therefore, we developed Bio‐Cy, an unprecedented organic unimolecular photosensitive immunostimulant, which stimulates self‐amplifying pyroptosis and cGAS‐STING pathways by disrupting pyroptosis checkpoints to enhance adaptive and innate immunity activation. Mechanistic studies have shown that Bio‐Cy can target cancer cells and be transported to lysosomes via endocytosis, generating reactive oxygen species through a Type I photodynamic mechanism to destroy cancer cells, even under hypoxic conditions. Interestingly, this lysosomal disruption not only activates the caspase‐3/GSDME‐dependent pyroptosis of adaptive immunity through mitochondrial damage by releasing Ca2+, but also enhances the cGAS‐STING innate immune pathway by releasing mitochondrial DNA. More importantly, the initial lysosomal damage impairs protective cellular autophagy, destroying the pyroptosis checkpoint and thus preventing the clearance of damaged mitochondria and amplifying immune responses, ultimately boosting immunotherapy. This strategy effectively treats primary tumors and inhibits metastatic growth, offering a new paradigm for photoimmunotherapy.
- 9 June 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (59) , 10981-10984
Switching between type I/II photosensitization processes for of an unconventional dye as modulated by the tumor microenvironment for inducing immunogenic death
In this work, an unconventional Se-substituted hemicyanine dye (HCySe–O–NO2) decorated with a p-nitrophenyl moiety as a recognition site was investigated. Its type I/II photosensitization processes could be regulated by the tumor microenvironment, alleviating the oxygen dependence of conventional photodynamic therapy (PDT) for the treatment of solid tumors. Upon being exposed to 760-nm-wavelength laser irradiation, cancer cells treated with HCySe–O–NO2 exhibited the phenomenon of pyroptosis, resulting in an amplification of cellular immunogenic death (ICD), and hence demonstrating the potential value of this dye for photoimmunotherapy.
- 9 June 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (59) , 10981-10984
Switching between type I/II photosensitization processes for of an unconventional dye as modulated by the tumor microenvironment for inducing immunogenic death
In this work, an unconventional Se-substituted hemicyanine dye (HCySe–O–NO2) decorated with a p-nitrophenyl moiety as a recognition site was investigated. Its type I/II photosensitization processes could be regulated by the tumor microenvironment, alleviating the oxygen dependence of conventional photodynamic therapy (PDT) for the treatment of solid tumors. Upon being exposed to 760-nm-wavelength laser irradiation, cancer cells treated with HCySe–O–NO2 exhibited the phenomenon of pyroptosis, resulting in an amplification of cellular immunogenic death (ICD), and hence demonstrating the potential value of this dye for photoimmunotherapy.
- Open Access
- 13 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (9) , e2409007
A One Stone Three Birds Paradigm of Photon‐Driven Pyroptosis Dye for Amplifying Tumor Immunotherapy
Activating the pyroptosis pathway of tumor cells by photodynamic therapy (PDT) for immunogenic cell death (ICD) is considered a valid strategy in pursuit of antitumor immunotherapy, but it remains a huge challenge due to the lack of reliable design guidelines. Moreover, it is often overlooked that conventional PDT can exacerbate the development of tumor immunosuppressive microenvironment, which is apparently unfavorable to clinical immunotherapy. The endoplasmic reticulum's (ER) pivotal role in cellular homeostasis and its emerging link to pyroptosis have galvanized interest in ER‐centric imaging and therapeutics. Herein, using the targeted group‐assisted strategy (TAGS), an intriguing cyclooxygenase‐2‐targeted photodynamic conjugate, Indo‐Cy, strategically created, which exploits the enzyme's overabundance in the tumoral ER, especially under proinflammatory hypoxic conditions. This conjugate, with its highly precise ER imaging, embodies a trifunctional strategy: i) innovating an electron transfer mechanism, converting the hemicyanine moiety into an oxygen‐independent type I photosensitizer, thereby navigating around the hypoxia constraints of traditional PDT; ii) executing precise ER‐targeted PDT, amplifying caspase‐1/GSDMD‐mediated pyroptosis for ICD; 3) attenuating immunosuppressive pathways by inhibiting cyclooxygenase‐2 downstream factors, including HIF‐1α, PGE2, and VEGF. Indo‐Cy's multimodal approach potently induces in vivo tumor pyroptosis and bolsters antitumor immunity, underscoring cyclooxygenase‐2‐targeted dyes' potential as a versatile oncotherapeutics.
- 13 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (9) , e2409007
Open AccessA One Stone Three Birds Paradigm of Photon‐Driven Pyroptosis Dye for Amplifying Tumor Immunotherapy
Activating the pyroptosis pathway of tumor cells by photodynamic therapy (PDT) for immunogenic cell death (ICD) is considered a valid strategy in pursuit of antitumor immunotherapy, but it remains a huge challenge due to the lack of reliable design guidelines. Moreover, it is often overlooked that conventional PDT can exacerbate the development of tumor immunosuppressive microenvironment, which is apparently unfavorable to clinical immunotherapy. The endoplasmic reticulum's (ER) pivotal role in cellular homeostasis and its emerging link to pyroptosis have galvanized interest in ER‐centric imaging and therapeutics. Herein, using the targeted group‐assisted strategy (TAGS), an intriguing cyclooxygenase‐2‐targeted photodynamic conjugate, Indo‐Cy, strategically created, which exploits the enzyme's overabundance in the tumoral ER, especially under proinflammatory hypoxic conditions. This conjugate, with its highly precise ER imaging, embodies a trifunctional strategy: i) innovating an electron transfer mechanism, converting the hemicyanine moiety into an oxygen‐independent type I photosensitizer, thereby navigating around the hypoxia constraints of traditional PDT; ii) executing precise ER‐targeted PDT, amplifying caspase‐1/GSDMD‐mediated pyroptosis for ICD; 3) attenuating immunosuppressive pathways by inhibiting cyclooxygenase‐2 downstream factors, including HIF‐1α, PGE2, and VEGF. Indo‐Cy's multimodal approach potently induces in vivo tumor pyroptosis and bolsters antitumor immunity, underscoring cyclooxygenase‐2‐targeted dyes' potential as a versatile oncotherapeutics.
- 3 June 2024
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 672, 350-362
Synthetic genomic nanomedicine with triple-responsiveness for systemic anti-tumor therapy
- 3 June 2024
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 672, 350-362
Synthetic genomic nanomedicine with triple-responsiveness for systemic anti-tumor therapy
- 15 September 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (19) , 18263-18274
Nanomicelle-Based Redox-Responsive Dual-Prodrug for Synergistic Breast Cancer Chemo-Immunotherapy
- 15 September 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (19) , 18263-18274
Nanomicelle-Based Redox-Responsive Dual-Prodrug for Synergistic Breast Cancer Chemo-Immunotherapy
- Top Cited Papers
- 24 July 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 52 (16) , 5607-5651
Fluorescent dyes based on rhodamine derivatives for bioimaging and therapeutics: recent progress, challenges, and prospects
Since their inception, rhodamine dyes have been extensively applied in biotechnology as fluorescent markers or for the detection of biomolecules owing to their good optical physical properties. Accordingly, they have emerged as a powerful tool for the visualization of living systems. In addition to fluorescence bioimaging, the molecular design of rhodamine derivatives with disease therapeutic functions (e.g., cancer and bacterial infection) has recently attracted increased research attention, which is significantly important for the construction of molecular libraries for diagnostic and therapeutic integration. However, reviews focusing on integrated design strategies for rhodamine dye-based diagnosis and treatment and their wide application in disease treatment are extremely rare. In this review, first, a brief history of the development of rhodamine fluorescent dyes, the transformation of rhodamine fluorescent dyes from bioimaging to disease therapy, and the concept of optics-based diagnosis and treatment integration and its significance to human development are presented. Next, a systematic review of several excellent rhodamine-based derivatives for bioimaging, as well as for disease diagnosis and treatment, is presented. Finally, the challenges in practical integration of rhodamine-based diagnostic and treatment dyes and the future outlook of clinical translation are also discussed.
- 24 July 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 52 (16) , 5607-5651
Top Cited PapersFluorescent dyes based on rhodamine derivatives for bioimaging and therapeutics: recent progress, challenges, and prospects
Since their inception, rhodamine dyes have been extensively applied in biotechnology as fluorescent markers or for the detection of biomolecules owing to their good optical physical properties. Accordingly, they have emerged as a powerful tool for the visualization of living systems. In addition to fluorescence bioimaging, the molecular design of rhodamine derivatives with disease therapeutic functions (e.g., cancer and bacterial infection) has recently attracted increased research attention, which is significantly important for the construction of molecular libraries for diagnostic and therapeutic integration. However, reviews focusing on integrated design strategies for rhodamine dye-based diagnosis and treatment and their wide application in disease treatment are extremely rare. In this review, first, a brief history of the development of rhodamine fluorescent dyes, the transformation of rhodamine fluorescent dyes from bioimaging to disease therapy, and the concept of optics-based diagnosis and treatment integration and its significance to human development are presented. Next, a systematic review of several excellent rhodamine-based derivatives for bioimaging, as well as for disease diagnosis and treatment, is presented. Finally, the challenges in practical integration of rhodamine-based diagnostic and treatment dyes and the future outlook of clinical translation are also discussed.